Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score
To compare an MRI-based radiomics signature with the programmed cell death ligand 1 (PD-L1) expression score for predicting immunotherapy response in nasopharyngeal carcinoma (NPC). Consecutive patients with NPC who received immunotherapy between January 2019 and June 2022 were divided into training...
Gespeichert in:
Veröffentlicht in: | European radiology 2025-01 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | European radiology |
container_volume | |
creator | Mai, Hui Li, Li Xin, Xin Jiang, Zhike Tang, Yongfang Huang, Jie Lei, Yanxing Chen, Lianzhi Dong, Tianfa Zhong, Xi |
description | To compare an MRI-based radiomics signature with the programmed cell death ligand 1 (PD-L1) expression score for predicting immunotherapy response in nasopharyngeal carcinoma (NPC).
Consecutive patients with NPC who received immunotherapy between January 2019 and June 2022 were divided into training (n = 111) and validation (n = 66) sets. Tumor radiomics features were extracted from pretreatment MR images. PD-L1 combined positive score (CPS) was calculated using immunohistochemistry. The least absolute shrinkage and selection operator (LASSO) algorithm was used for feature selection and radiomics signature construction. Receiver operating characteristic (ROC) curve analysis was performed to assess prediction performance.
A total of eleven radiomics features with the greatest discrimination capability were identified by the LASSO algorithm to construct the radiomics signature. In predicting patients with objective response to immunotherapy, radiomics score (Rd-score) yielded a significantly higher area under the ROC curve than that of CPS in both the training (0.790 vs. 0.645, p = 0.025) and the validation (0.735 vs. 0.608, p = 0.038) sets. Multivariate analysis identified the Rd-score as an independent influencing factor in predicting immunotherapy response (odds ratio = 19.963, p |
doi_str_mv | 10.1007/s00330-025-11350-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3159688751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3159688751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c991-199adfe53c64b66eee3365633c4cfd1d7233cbcf47d3b39fcc2bd42c664da0643</originalsourceid><addsrcrecordid>eNpNkc1u1TAQhS1ERUvhBVigWbIJ2HGc3LBDFT-VWhWh7qOJPck1iu3gSRD3oXjH5nILYjVHmjOjM_MJ8UrJt0rK5h1LqbUsZGkKpbSRhXkiLlSly0LJXfX0P30unjN_l1K2qmqeiXPd7ozWWl2I318zOW8XnyKkAXwIa0zLnjLOB8jEc4pM4CNE5DTvMR_iSDiBxWx9TAHfA4JNYcaMi_9JwMvqDrCyjyPcfrsuemRykNH5FLxlYD9GXNZMgNHBnNOYMYTNYmmawBEue5j8eGwqoF_zloGP4dimTC_E2YAT08vHeinuP328v_pS3Nx9vr76cFPYtlWFalt0Axlt66qvayLSuja11rayg1OuKTfZ26FqnO51O1hb9q4qbV1XDmVd6Uvx5rR2i_djJV664PmYDyOllTutTFvvdo1Rm7U8WW1OzJmGbs4-bG_qlOyOlLoTpW6j1P2h1Jlt6PXj_rXfTv838heLfgDS75JW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3159688751</pqid></control><display><type>article</type><title>Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score</title><source>SpringerLink Journals - AutoHoldings</source><creator>Mai, Hui ; Li, Li ; Xin, Xin ; Jiang, Zhike ; Tang, Yongfang ; Huang, Jie ; Lei, Yanxing ; Chen, Lianzhi ; Dong, Tianfa ; Zhong, Xi</creator><creatorcontrib>Mai, Hui ; Li, Li ; Xin, Xin ; Jiang, Zhike ; Tang, Yongfang ; Huang, Jie ; Lei, Yanxing ; Chen, Lianzhi ; Dong, Tianfa ; Zhong, Xi</creatorcontrib><description>To compare an MRI-based radiomics signature with the programmed cell death ligand 1 (PD-L1) expression score for predicting immunotherapy response in nasopharyngeal carcinoma (NPC).
Consecutive patients with NPC who received immunotherapy between January 2019 and June 2022 were divided into training (n = 111) and validation (n = 66) sets. Tumor radiomics features were extracted from pretreatment MR images. PD-L1 combined positive score (CPS) was calculated using immunohistochemistry. The least absolute shrinkage and selection operator (LASSO) algorithm was used for feature selection and radiomics signature construction. Receiver operating characteristic (ROC) curve analysis was performed to assess prediction performance.
A total of eleven radiomics features with the greatest discrimination capability were identified by the LASSO algorithm to construct the radiomics signature. In predicting patients with objective response to immunotherapy, radiomics score (Rd-score) yielded a significantly higher area under the ROC curve than that of CPS in both the training (0.790 vs. 0.645, p = 0.025) and the validation (0.735 vs. 0.608, p = 0.038) sets. Multivariate analysis identified the Rd-score as an independent influencing factor in predicting immunotherapy response (odds ratio = 19.963, p < 0.001). Kaplan-Meier analysis indicated that patients with Rd-score ≥ 0.5 showed longer progression-free survival than patients with Rd-score < 0.5 (log-rank p < 0.01).
An MRI-based radiomics signature demonstrated greater efficacy than the PD-L1 expression score in predicting immunotherapy response in patients with NPC.
Question How does an MRI-based radiomics signature compare with the programmed cell death ligand 1 expression score for predicting immunotherapy response in nasopharyngeal carcinoma? Findings The MRI-based radiomics signature demonstrated superior predictive value compared with programmed cell death ligand 1 expression score in identifying immunotherapy responders. Clinical relevance MRI-based radiomics are a promising novel noninvasive tool for predicting immunotherapy outcomes in nasopharyngeal carcinoma.</description><identifier>ISSN: 1432-1084</identifier><identifier>EISSN: 1432-1084</identifier><identifier>DOI: 10.1007/s00330-025-11350-5</identifier><identifier>PMID: 39853331</identifier><language>eng</language><publisher>Germany</publisher><ispartof>European radiology, 2025-01</ispartof><rights>2025. The Author(s), under exclusive licence to European Society of Radiology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c991-199adfe53c64b66eee3365633c4cfd1d7233cbcf47d3b39fcc2bd42c664da0643</cites><orcidid>0000-0002-0713-105X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39853331$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mai, Hui</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Xin, Xin</creatorcontrib><creatorcontrib>Jiang, Zhike</creatorcontrib><creatorcontrib>Tang, Yongfang</creatorcontrib><creatorcontrib>Huang, Jie</creatorcontrib><creatorcontrib>Lei, Yanxing</creatorcontrib><creatorcontrib>Chen, Lianzhi</creatorcontrib><creatorcontrib>Dong, Tianfa</creatorcontrib><creatorcontrib>Zhong, Xi</creatorcontrib><title>Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score</title><title>European radiology</title><addtitle>Eur Radiol</addtitle><description>To compare an MRI-based radiomics signature with the programmed cell death ligand 1 (PD-L1) expression score for predicting immunotherapy response in nasopharyngeal carcinoma (NPC).
Consecutive patients with NPC who received immunotherapy between January 2019 and June 2022 were divided into training (n = 111) and validation (n = 66) sets. Tumor radiomics features were extracted from pretreatment MR images. PD-L1 combined positive score (CPS) was calculated using immunohistochemistry. The least absolute shrinkage and selection operator (LASSO) algorithm was used for feature selection and radiomics signature construction. Receiver operating characteristic (ROC) curve analysis was performed to assess prediction performance.
A total of eleven radiomics features with the greatest discrimination capability were identified by the LASSO algorithm to construct the radiomics signature. In predicting patients with objective response to immunotherapy, radiomics score (Rd-score) yielded a significantly higher area under the ROC curve than that of CPS in both the training (0.790 vs. 0.645, p = 0.025) and the validation (0.735 vs. 0.608, p = 0.038) sets. Multivariate analysis identified the Rd-score as an independent influencing factor in predicting immunotherapy response (odds ratio = 19.963, p < 0.001). Kaplan-Meier analysis indicated that patients with Rd-score ≥ 0.5 showed longer progression-free survival than patients with Rd-score < 0.5 (log-rank p < 0.01).
An MRI-based radiomics signature demonstrated greater efficacy than the PD-L1 expression score in predicting immunotherapy response in patients with NPC.
Question How does an MRI-based radiomics signature compare with the programmed cell death ligand 1 expression score for predicting immunotherapy response in nasopharyngeal carcinoma? Findings The MRI-based radiomics signature demonstrated superior predictive value compared with programmed cell death ligand 1 expression score in identifying immunotherapy responders. Clinical relevance MRI-based radiomics are a promising novel noninvasive tool for predicting immunotherapy outcomes in nasopharyngeal carcinoma.</description><issn>1432-1084</issn><issn>1432-1084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNpNkc1u1TAQhS1ERUvhBVigWbIJ2HGc3LBDFT-VWhWh7qOJPck1iu3gSRD3oXjH5nILYjVHmjOjM_MJ8UrJt0rK5h1LqbUsZGkKpbSRhXkiLlSly0LJXfX0P30unjN_l1K2qmqeiXPd7ozWWl2I318zOW8XnyKkAXwIa0zLnjLOB8jEc4pM4CNE5DTvMR_iSDiBxWx9TAHfA4JNYcaMi_9JwMvqDrCyjyPcfrsuemRykNH5FLxlYD9GXNZMgNHBnNOYMYTNYmmawBEue5j8eGwqoF_zloGP4dimTC_E2YAT08vHeinuP328v_pS3Nx9vr76cFPYtlWFalt0Axlt66qvayLSuja11rayg1OuKTfZ26FqnO51O1hb9q4qbV1XDmVd6Uvx5rR2i_djJV664PmYDyOllTutTFvvdo1Rm7U8WW1OzJmGbs4-bG_qlOyOlLoTpW6j1P2h1Jlt6PXj_rXfTv838heLfgDS75JW</recordid><startdate>20250124</startdate><enddate>20250124</enddate><creator>Mai, Hui</creator><creator>Li, Li</creator><creator>Xin, Xin</creator><creator>Jiang, Zhike</creator><creator>Tang, Yongfang</creator><creator>Huang, Jie</creator><creator>Lei, Yanxing</creator><creator>Chen, Lianzhi</creator><creator>Dong, Tianfa</creator><creator>Zhong, Xi</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0713-105X</orcidid></search><sort><creationdate>20250124</creationdate><title>Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score</title><author>Mai, Hui ; Li, Li ; Xin, Xin ; Jiang, Zhike ; Tang, Yongfang ; Huang, Jie ; Lei, Yanxing ; Chen, Lianzhi ; Dong, Tianfa ; Zhong, Xi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c991-199adfe53c64b66eee3365633c4cfd1d7233cbcf47d3b39fcc2bd42c664da0643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mai, Hui</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><creatorcontrib>Xin, Xin</creatorcontrib><creatorcontrib>Jiang, Zhike</creatorcontrib><creatorcontrib>Tang, Yongfang</creatorcontrib><creatorcontrib>Huang, Jie</creatorcontrib><creatorcontrib>Lei, Yanxing</creatorcontrib><creatorcontrib>Chen, Lianzhi</creatorcontrib><creatorcontrib>Dong, Tianfa</creatorcontrib><creatorcontrib>Zhong, Xi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mai, Hui</au><au>Li, Li</au><au>Xin, Xin</au><au>Jiang, Zhike</au><au>Tang, Yongfang</au><au>Huang, Jie</au><au>Lei, Yanxing</au><au>Chen, Lianzhi</au><au>Dong, Tianfa</au><au>Zhong, Xi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score</atitle><jtitle>European radiology</jtitle><addtitle>Eur Radiol</addtitle><date>2025-01-24</date><risdate>2025</risdate><issn>1432-1084</issn><eissn>1432-1084</eissn><abstract>To compare an MRI-based radiomics signature with the programmed cell death ligand 1 (PD-L1) expression score for predicting immunotherapy response in nasopharyngeal carcinoma (NPC).
Consecutive patients with NPC who received immunotherapy between January 2019 and June 2022 were divided into training (n = 111) and validation (n = 66) sets. Tumor radiomics features were extracted from pretreatment MR images. PD-L1 combined positive score (CPS) was calculated using immunohistochemistry. The least absolute shrinkage and selection operator (LASSO) algorithm was used for feature selection and radiomics signature construction. Receiver operating characteristic (ROC) curve analysis was performed to assess prediction performance.
A total of eleven radiomics features with the greatest discrimination capability were identified by the LASSO algorithm to construct the radiomics signature. In predicting patients with objective response to immunotherapy, radiomics score (Rd-score) yielded a significantly higher area under the ROC curve than that of CPS in both the training (0.790 vs. 0.645, p = 0.025) and the validation (0.735 vs. 0.608, p = 0.038) sets. Multivariate analysis identified the Rd-score as an independent influencing factor in predicting immunotherapy response (odds ratio = 19.963, p < 0.001). Kaplan-Meier analysis indicated that patients with Rd-score ≥ 0.5 showed longer progression-free survival than patients with Rd-score < 0.5 (log-rank p < 0.01).
An MRI-based radiomics signature demonstrated greater efficacy than the PD-L1 expression score in predicting immunotherapy response in patients with NPC.
Question How does an MRI-based radiomics signature compare with the programmed cell death ligand 1 expression score for predicting immunotherapy response in nasopharyngeal carcinoma? Findings The MRI-based radiomics signature demonstrated superior predictive value compared with programmed cell death ligand 1 expression score in identifying immunotherapy responders. Clinical relevance MRI-based radiomics are a promising novel noninvasive tool for predicting immunotherapy outcomes in nasopharyngeal carcinoma.</abstract><cop>Germany</cop><pmid>39853331</pmid><doi>10.1007/s00330-025-11350-5</doi><orcidid>https://orcid.org/0000-0002-0713-105X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1432-1084 |
ispartof | European radiology, 2025-01 |
issn | 1432-1084 1432-1084 |
language | eng |
recordid | cdi_proquest_miscellaneous_3159688751 |
source | SpringerLink Journals - AutoHoldings |
title | Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T01%3A53%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prediction%20of%20immunotherapy%20response%20in%20nasopharyngeal%20carcinoma:%20a%20comparative%20study%20using%20MRI-based%20radiomics%20signature%20and%20programmed%20cell%20death%20ligand%201%20expression%20score&rft.jtitle=European%20radiology&rft.au=Mai,%20Hui&rft.date=2025-01-24&rft.issn=1432-1084&rft.eissn=1432-1084&rft_id=info:doi/10.1007/s00330-025-11350-5&rft_dat=%3Cproquest_cross%3E3159688751%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3159688751&rft_id=info:pmid/39853331&rfr_iscdi=true |